Ferring’s Degarelix Effectively Cut Testosterone Levels In Phase III Prostate Cancer Trial
This article was originally published in The Pink Sheet Daily
However, more details are needed before clinicians get excited about this drug, one oncologist tells “The Pink Sheet” DAILY.
You may also be interested in...
Swiss-drug maker Ferring launched its rapid onset prostate cancer treatment degarelix in the U.S. and Europe in March, marking the firm's first global launch
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.